الفهرس | Only 14 pages are availabe for public view |
Abstract This study aimed to assess serotonin transporter polymorphism in PDE-5 inhibitors non-responders. In all, 340 men presented to the University hospitals after ethical approval and informed consent. They were allocated into: Healthy potent men (n=170) Men with ED non-responders for sildenafil (n=170) Inclusion criteria for PDE-5Is non-responders: An inadequate erectile response after 6 attempts using high tolerated dose (100 mg) with manufacturer’s guidelines in respect to time relative to meals, associated medications and sexual stimulation/ arousal. Exclusion criteria: Diabetes, smoking, hypertension, dyslipidemia, hypogonadism, cardiovascular disorders, morbid obesity and hepatic/renal failure. They were subjected to: History taking, clinical examination, IIEF-5 questionnaire and detection of 5-HTTLPR (serotonin transporter promoter gene) genotyping by PCR. The results were as follows: 1. In potent controls, SS genotypes demonstrated significant increase whereas LL genotypes demonstrated significant decrease compared with ED men non-responders to sildenafil citrate. 2. SL/LL genotyping demonstrated significant increase in ED men non-responders to sildenafil citrate compared with potent men (relative risk 6.0). 3. In ED men non-responders for sildenafil citrate, the frequency of S allele demonstrated significant decrease and the frequency of L allele demonstrated significant increase compared with the potent controls. 4. 5-HTTLPR genotypes demonstrated significant negative correlation with IIEF-5 and significant positive correlation with age. IIEF-5 demonstrated significant negative correlation with age. Conclusion: 5-HTTLPR polymorphism play a role of male sexual health being significantly represented in men with ED non-responding for sildenafil citrate. |